- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging therapies in mantle cell lymphoma
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-17
DOI
10.1186/s13045-020-00914-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
- (2020) Rajat Bannerji et al. BLOOD
- First-in-Human, Phase 1/2 Trial to Assess the Safety and Clinical Activity of Subcutaneous GEN3013 (DuoBody®-CD3×CD20) in B-Cell Non-Hodgkin Lymphomas
- (2020) Pieternella Lugtenburg et al. BLOOD
- Results from a First-in-Human, Proof-of-Concept Phase 1 Trial in Pretreated B-Cell Malignancies for Loxo-305, a Next-Generation, Highly Selective, Non-Covalent BTK Inhibitor
- (2020) Anthony R. Mato et al. BLOOD
- Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial
- (2020) Constantine S. Tam et al. BLOOD
- Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
- (2020) Stephen J Schuster et al. BLOOD
- Three Year Update of the Phase II ABT-199 (Venetoclax) and Ibrutinib in Mantle Cell Lymphoma (AIM) Study
- (2020) Sasanka M. Handunnetti et al. BLOOD
- DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
- (2020) Patrick J. Engelberts et al. EBioMedicine
- Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial
- (2020) Jeanette K. Doorduijn et al. BRITISH JOURNAL OF HAEMATOLOGY
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
- (2019) James N. Gerson et al. JOURNAL OF CLINICAL ONCOLOGY
- Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
- (2019) Franck Morschhauser et al. Lancet Haematology
- A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
- (2019) Peter Martin et al. BLOOD
- Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
- (2019) Dana Prukova et al. CLINICAL CANCER RESEARCH
- Increased Tumor Angiogenesis in SOX 11‐positive Mantle Cell Lymphoma
- (2019) Georgios Petrakis et al. HISTOPATHOLOGY
- Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2019) Yunhang Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
- (2019) Michael Wang et al. LEUKEMIA
- Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations
- (2019) Eliana B. Gomez et al. BLOOD
- Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
- (2019) Jennifer Woyach et al. BLOOD
- Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial
- (2019) Martin Dreyling et al. BLOOD
- Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial
- (2019) Preetesh Jain et al. BLOOD
- Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age (PrE0405): A Phase II Study
- (2019) Craig A. Portell et al. BLOOD
- Ibrutinib, Venetoclax Plus Obinutuzumab in Newly Diagnosed Mantle Cell Lymphoma Patients
- (2019) Steven Le Gouill et al. BLOOD
- A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
- (2019) Brad S. Kahl et al. CLINICAL CANCER RESEARCH
- The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs
- (2019) Debora Soncini et al. HAEMATOLOGICA
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma
- (2019) Michael A. Dengler et al. ONCOGENE
- A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma
- (2018) Hun J. Lee et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma
- (2018) Jorge E. Romaguera et al. CANCER
- Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia
- (2018) Michael Y. Choi et al. Cell Stem Cell
- A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
- (2018) Marek Trněný et al. HAEMATOLOGICA
- Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study
- (2018) Anastasios Stathis et al. INVESTIGATIONAL NEW DRUGS
- Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial
- (2018) Michael Wang et al. LANCET
- Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis
- (2018) Chintan Shah et al. LEUKEMIA & LYMPHOMA
- Role of Bruton’s tyrosine kinase in B cells and malignancies
- (2018) Simar Pal Singh et al. Molecular Cancer
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma
- (2018) Jian Yu et al. Oncotarget
- A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy
- (2018) Marek Trněný et al. HAEMATOLOGICA
- Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
- (2018) Mats Jerkeman et al. Lancet Haematology
- Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study
- (2018) S de Vos et al. ANNALS OF ONCOLOGY
- Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma
- (2018) Jia Ruan et al. BLOOD
- Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib
- (2018) Preetesh Jain et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
- (2018) Franck Morschhauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
- (2018) Sean D. Reiff et al. Cancer Discovery
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia
- (2017) Swapna Thota et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a “real world” study
- (2017) Narendranath Epperla et al. HEMATOLOGICAL ONCOLOGY
- Ibrutinib treatment improves T cell number and function in CLL patients
- (2017) Meixiao Long et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- (2017) Matthew S. Davids et al. JOURNAL OF CLINICAL ONCOLOGY
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition
- (2017) Joyoti Dey et al. Scientific Reports
- Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma
- (2016) D. Chiron et al. BLOOD
- Postibrutinib outcomes in patients with mantle cell lymphoma
- (2016) P. Martin et al. BLOOD
- Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
- (2016) A. Albertsson-Lindblad et al. BLOOD
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma
- (2016) Bertrand Coiffier et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study
- (2016) Maria-Elisabeth Goebeler et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study
- (2016) Martin Dreyling et al. LANCET
- Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
- (2016) Michael L Wang et al. LANCET ONCOLOGY
- Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
- (2016) Marek Trněný et al. LANCET ONCOLOGY
- Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
- (2016) Maria-Elisabeth Goebeler et al. LEUKEMIA & LYMPHOMA
- Invasive Candidiasis
- (2016) NEW ENGLAND JOURNAL OF MEDICINE
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
- (2015) M. L. Wang et al. BLOOD
- Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
- (2015) E. A. Chong et al. CLINICAL CANCER RESEARCH
- Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation
- (2015) Jian Yu et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas
- (2015) Peter Martin et al. LEUKEMIA & LYMPHOMA
- Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
- (2015) Jia Ruan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I/II Study of Bortezomib-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin Lymphoma, Transformed, or Mantle Cell Lymphoma
- (2014) Basem M. William et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
- (2014) K. Maddocks et al. BLOOD
- Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells
- (2014) Jiao Ma et al. BRITISH JOURNAL OF HAEMATOLOGY
- Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma
- (2014) Daniel A. Heinrich et al. BRITISH JOURNAL OF HAEMATOLOGY
- Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways
- (2014) Xiaoxian Zhao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™therapeutic protein, for relapsed or refractory NHL patients
- (2014) John M. Pagel et al. BRITISH JOURNAL OF HAEMATOLOGY
- Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
- (2013) P. L. Zinzani et al. ANNALS OF ONCOLOGY
- A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies
- (2013) J. Deckert et al. BLOOD
- Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
- (2013) Julie M. Vose et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide Inhibits Lymphangiogenesis in Preclinical Models of Mantle Cell Lymphoma
- (2013) K. Song et al. CANCER RESEARCH
- Induction of prolonged early G1arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1
- (2013) David Chiron et al. CELL CYCLE
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Franck Andre Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- In VitroandIn VivoTherapeutic Efficacy of Carfilzomib in Mantle Cell Lymphoma: Targeting the Immunoproteasome
- (2013) Liang Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
- (2012) J. P. Leonard et al. BLOOD
- New Strategies in the Treatment of Mantle Cell Lymphoma
- (2012) C. Deng et al. CLINICAL CANCER RESEARCH
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
- (2012) Michael Wang et al. LANCET ONCOLOGY
- FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death
- (2011) L. Alinari et al. BLOOD
- ROR1 expression is not a unique marker of CLL
- (2010) Gábor Barna et al. HEMATOLOGICAL ONCOLOGY
- Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
- (2009) Liang Zhang et al. AMERICAN JOURNAL OF HEMATOLOGY
- Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
- (2009) C. Pott et al. BLOOD
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
- (2009) Thomas M. Habermann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
- (2007) E. Hoster et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started